Registered outcomes14

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

1 to 14 of 14

List	Outcome	Time frame	Description
Primary	Hierarchical Composite Clinical Outcome Assessed Using the Win Odds/Win Ratio	Day 30	Hierarchical composite of death, new extracorporeal membrane oxygenation (ECMO), new invasive mechanical ventilation, CTCAE grade 4 adverse drug reactions considered at least probably related to treatment, new non-invasive ventilation, change in PCP therapy due to presumed treatment failure or a probable adverse drug reaction, and hospital length of stay among survivors. Assessed using the Win Odds approach.
Secondary	Proportion of participants who died	Through Day 30	Proportion of participants who died
Secondary	Hospital length of stay among survivors	Through Day 30	Length of hospital stay among participants who survive.
Secondary	CTCAE grade 3 and 4 adverse drug reactions	Through Day 30	Proportion of participants with CTCAE grade 3 or 4 adverse drug reactions considered at least probably related to treatment, by organ system.
Secondary	Time to occurrence of primary outcome components	Through Day 30	Time to each component of the primary outcome, including death, new respiratory support, treatment changes, and severe adverse drug reactions.
Secondary	Proportion of patients requiring new ECMO	Through Day 30	Proportion of patients requiring new extracorporeal membrane oxygenation
Secondary	Proportion of patients requiring new mechanical ventilation	Through Day 30	Proportion of patients requiring new mechanical ventilation
Secondary	Proportion of patients with CTCAE grade 4 adverse drug reactions considered at least probably related to treatment	Through day 30	Proportion of patients with CTCAE grade 4 adverse drug reactions considered at least probably related to treatment
Secondary	Proportion of patients requiring new non-invasive ventilation,	Through day 30	Proportion of patients requiring new non-invasive ventilation,
Secondary	Proportion of patients with change in PCP therapy due to presumed treatment failure or a probable adverse drug reaction	Through day 30	Proportion of patients with change in PCP therapy due to presumed treatment failure or a probable adverse drug reaction
Other	Health-related quality of life	Days 30 and 180	Quality of life measured using the EQ-5D-5L (EuroQol 5-Dimension 5-Level) questionnaire The EQ-5D-5L measures health-related quality of life using a two-part self-report questionnaire that evaluates functional status across five core dimensions and records an overall self-rated health score
Other	Recurrence of PCP infection	Through Day 180	Occurrence of recurrent Pneumocystis jirovecii pneumonia.
Other	All-cause mortality	Through Day 180	Death from any cause.
Other	Quality of life using the visual analogue scale (VAS)	Day 30, day 180	VAS rates overall health from 0 (worst imaginable health) to 100 (best imaginable health), where higher values are better

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT07900373/registered

API reference For AI assistants